公开(公告)号：US20050222235A1

公开(公告)日：2005-10-06

申请号：US10520781

申请日：2003-07-14

申请人： Yoshihiro Urade ,  Naomi Eguchi ,  Kosuke Aritake ,  Yo Sato ,  Keiichi Kadoyama ,  Masako Taniike

发明人： Yoshihiro Urade ,  Naomi Eguchi ,  Kosuke Aritake ,  Yo Sato ,  Keiichi Kadoyama ,  Masako Taniike

IPC分类号： A61K31/381 ,  A61K31/454 ,  A61K31/53 ,  A61K45/06 ,  A61P25/00 ,  A61P43/00 ,  C07D333/68 ,  G01N33/50 ,  G01N33/68 ,  G01N33/88 ,  A61K31/4164 ,  A61K31/403

CPC分类号： A61K45/06 ,  A61K31/381 ,  A61K31/454 ,  A61K31/53 ,  G01N33/5088 ,  G01N33/6896 ,  G01N33/88

摘要： There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.

公开(公告)号：US20050227984A1

公开(公告)日：2005-10-13

申请号：US11139530

申请日：2005-05-31

申请人： Yoshihiro Urade ,  Naomi Eguchi ,  Kosuke Aritake ,  Yo Sato ,  Keiichi Kadoyama ,  Masako Taniike

发明人： Yoshihiro Urade ,  Naomi Eguchi ,  Kosuke Aritake ,  Yo Sato ,  Keiichi Kadoyama ,  Masako Taniike

IPC分类号： A61K31/381 ,  A61K31/454 ,  A61K31/53 ,  A61K45/06 ,  A61P25/00 ,  A61P43/00 ,  C07D333/68 ,  G01N33/50 ,  G01N33/68 ,  G01N33/88 ,  A61K31/558

CPC分类号： A61K45/06 ,  A61K31/381 ,  A61K31/454 ,  A61K31/53 ,  G01N33/5088 ,  G01N33/6896 ,  G01N33/88

摘要： There are provided a compound for treatment or prevention of brain injury caused by diseases such as cerebrovascular disorder, brain degenerative disease and demyelinating disease and a method for screening the same. Brain injury in which prostaglandin D2 is participated is treated or prevented by inhibition of hematopoietic prostaglandin D synthase induced in microglia cell or macrophage of brain injury area by diseases such as cerebrovascular disorder, brain degenerative disease or demyelinating disease or by inhibition of activation of prostaglandin D receptor expressed in astroglia cell around the injured area. There is also provided a method of testing those pharmaceutical substances using a transgenic mouse in which human hematopoietic prostaglandin D synthase is expressed in large amounts.

摘要翻译： 提供了治疗或预防由脑血管障碍，脑退行性疾病和脱髓鞘疾病等疾病引起的脑损伤的化合物及其筛选方法。 通过抑制由脑血管障碍，脑退行性疾病或脱髓鞘疾病等脑损伤区域的小胶质细胞或巨噬细胞诱导的造血前列腺素D合成酶来治疗或预防前列腺素D 2 2参与的脑损伤 或通过抑制在损伤区域周围的星形胶质细胞中表达的前列腺素D受体的活化来抑制。 还提供了使用其中大量表达人造血前列腺素D合成酶的转基因小鼠来测试这些药物的方法。